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Objectives: Chlamydia pneumoniae has been related to atherosclerotic disease in both seroepidemiologic and genomic
studies. We performed a case-control study to determine seropositivity and DNA detection in arteries of patients with
peripheral artery occlusive disease and of healthy subjects.
Methods: The study included 64 patients with peripheral artery occlusive disease, and 50 control subjects who underwent
varicose vein surgery, matched to the patient group for age, sex, and tobacco use. The fibrinogen level in all study subjects
was measured as a marker of inflammation. Blood samples were taken from all subjects for determination of immuno-
globulin (Ig) G elementary bodies (EB) against C pneumoniae with microimmunofluorescence (MIF) and enzyme-linked
immunosorbent assay (ELISA), and of IgA EB with ELISA. The cutoff titers were 1:32 for MIF and 1.1 for ELISA.
Biopsy specimens of arterial atheromatous plaque were obtained from patients, and of pudendal artery and saphenous
vein from control subjects, and were studied with hemi-nested polymerase chain reaction.
Results: There were no differences in fibrinogen level between patients and controls. The prevalence of IgG anti-EB with
MIF was 78% in patients and 24% in control subjects (P .0001; odds ratio [OR], 11.3; 95% confidence interval [CI],
4.7-27.2). Prevalence of IgG anti-EB with ELISA was 75% in patients and 16% in control subjects (P .0001; OR, 15.7;
95% CI, 6.1-40). There were no differences in IgA anti-EB titers. Bacterial DNA was detected in 67% of atheromatous
plaques versus 12% of pudendal arteries (P  .0001) and 4% of saphenous veins. A weak correlation was found between
seropositivity and the presence of intravascular DNA.
Conclusions: Our results support the hypothesis that C pneumoniae is related to the pathogenesis of atherosclerotic
peripheral artery occlusive disease. (J Vasc Surg 2004;40:359-66.)
Clinical Relevance: This study explored the infectious hypothesis in the context of the pathogenesis of atherosclerosis.
This hypothesis has been supported by findings that certain infectious agents can cause or accelerate the course of diseases
in which the possibility of a microbial cause was not previously proposed, as in the case of peptic ulcer and spongiform
encephalopathy. The present study demonstrated the presence of Chlamydia pneumoniae and seropositivity in athero-
matous plaques in patients with peripheral artery occlusive disease. These results contribute to a body of research that is
opening up the possibility of treating atherosclerotic disease with antibiotic agents, and preventing it with immunization.The infectious pathogenesis of atherosclerosis was orig-
inally proposed by Osler in 1908, but was rapidly discarded
after failure to isolate any pathogen responsible.1 Athero-
sclerosis was subsequently associated with herpes simplex
virus and cytomegalovirus.2,3 Not until 1988 did Saikku et
al4 publish the first seroepidemiologic study that reported
high titers of circulating antibodies against Chlamydia
pneumoniae5 in patients with coronary atherosclerosis.
These findings were corroborated by Thom et al,6 who
discovered the bacteria in 1991, and Saikku et al7 repeated
their own results in a wider study in 1992. Later studies also
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doi:10.1016/j.jvs.2004.04.027demonstrated the presence of circulating immunocom-
plexes against C pneumoniae in patients with ischemic heart
disease.8 In 1992 C pneumoniae in atherosclerotic vascular
tissue was first reported,9 detected with immunocytochem-
istry. This microorganism has also been detected with
electronic microscopy and polymerase chain reaction
(PCR) studies, and at culture of biopsy specimens of the
atherosclerotic aortic, coronary, femoral, and carotid artery
walls.10 Several subsequent studies have suggested that
chronic infection with C pneumoniae may contribute to the
pathogenesis of atherosclerosis.11,12
The objective of the present case-control study was to
assess the relationship between C pneumoniae and periph-
eral artery occlusive disease (PAOD) involving the carotid,
femoral, and aortoiliac arteries. The study comprised 3
parts: clinical study (inflammation markers), study of im-
mune response, and detection of C pneumoniae DNA in
samples of arterial wall from patients and control subjects.
METHODS
An observational, analytical case-control study was
conducted in 114 patients treated in the Vascular Surgery
Department at our center. All laboratory determinations,359
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of C pneumoniae DNA, were processed and interpreted in
blinded fashion.
Patients. One hundred twenty-six consecutive pa-
tients who required revascularization surgery to treat
PAOD at various sites were recruited for the study. Thirty-
nine patients with active inflammatory or infectious pro-
cesses were excluded, as were 23 patients with Fontaine
grade IV lower limb ischemia. Therefore there were 64
patients, all with Fontaine grade II or III disease. Further
information on anatomic subgroups and clinical character-
istics of these patients is given in Table I. The control group
comprised 50 subjects with chronic superficial venous
insufficiency.
It should be borne in mind that the control subjects
were recruited from among patients who underwent sur-
gery to treat chronic venous insufficiency, consisting of
saphenectomy under regional or general anesthesia, and all
had C2 or C3 disease, according to the CEAP classification
system. Consequently all control subjects underwent gen-
eral examination in the Anesthesia Department, including
electrocardiography, chest x-ray studies, blood and bio-
chemical analyses, and circulatory examination. In all con-
trol subjects anesthetic risk was American Society of Anes-
thesiologists (ASA) I or II. Control subjects with coronary,
pulmonary, or renal disease, either previously known or
discovered during the preoperative examination, were ex-
cluded from the study. The absence of posterior tibial pulse
or dorsal pedal pulse was an exclusion criterion, but no
patients were excluded for this reason. All control subjects
underwent carotid duplex ultrasound scanning, and none
demonstrated stenosis greater than 20%.
Patients and control subjects enrolled in the study were
interviewed regarding previous genitourinary infections, to
avert possible serologic cross-reactions between C pneu-
moniae and Chlamydia trachomatis. No history of these
infections was reported by any subject. For the same reason,
patients with chronic respiratory disease or pneumonia in
the previous 3 months were excluded, to avert cross-reac-
tions with Chlamydia psittaci. We also excluded patients
with any chronic inflammatory or infectious diseases other
than atherosclerosis. To prevent the possible elimination of
C pneumoniae with use of antibiotic agents, patients who
Table I. Anatomic-clinical subgroups of patients with





Cerebrovascular disease 26 21, stroke plus ICA stenosis
70%
5, ICA stenosis 99%
Aortoiliac disease 18 10, G-II (Fontaine)
8, G-III (Fontaine)
Femoropopliteal disease 20 5, G-II (Fontaine)
15, G-III (Fontaine)
ICA, Internal carotid artery.received antibiotic therapy for any reason in the previous 3
months were excluded, as were subjects allergic to -lac-
tam, because our antibiotic prophylaxis for these patients is
with erythromycin, an effective antibiotic against C pneu-
moniae.
All subjects selected for the study signed informed
consent forms to participate. The study was approved by
the ethics committee at our center.
Clinical determinations. Clinical and analytical data
considered included sex, exposure to tobacco, obesity
(30% above theoretical weight), systolic arterial blood
pressure, hypertension, cholesterol concentration, hyper-
cholesterolemia, triglyceride concentration, and hypertri-
glyceridemia. Current smokers and ex-smokers who had
smoked for more than 10 years were considered exposed to
tobacco.
Marker of inflammation. Fibrinogen levels were al-
ways determined (P-T Fibrinogen HS) before surgery, with
the derived fibrinogen assay.
Antibody determinations. Immunoglobulin (Ig) G
to elementary body (EB) of C pneumoniae was studied with
two analytic techniques: indirect microimmunofluores-
cence (MIF; MRL Chlamydia pneumoniae IgG MIF), per-
formed as described,13,14 and enzyme-linked immunosor-
bent assay (ELISA; Chlamydia pneumoniae IgG Vircell), as
described.15 For greater precision, the process was auto-
mated with the use of a sample dilutor (TECAN Megaflex)
and plate processor for ELISA (BEP III; Dade Behring). A
single experienced researcher made the MIF observations,
which were carried out in duplicate to confirm their valid-
ity. Before evaluation of the results, 10% of the samples
were retested, and similar results were obtained.
For the MIF technique we considered all titers 1:32 or
greater as positive. IgA to EB was also studied with ELISA
(C pneumoniae IgA Vircell), with use of Chlamydia outer
membrane complexes. Absorbance was measured at 450 or
620 nm. Results were expressed as indexes by dividing the
absorbance of the sample by that of the cutoff. Indexes less
than 0.9 were scored as negative, 0.9 to 1.1 as uncertain,
and greater than 1.1 as positive. Studies with uncertain
results were repeated, and the new result was taken as valid.
For greater precision the process was automated with the
use of a sample dilutor (TECAN Megaflex) and plate
processor (BEP III; Dade Behring). Before evaluation of
the results, 10% of the samples were retested, and similar
results were obtained.
Determination of C pneumoniae DNA in biopsy
specimens. In the patient group, histologic samples were
obtained from the atheromatous plaques collected during
carotid thromboendarterectomy, femoropopliteal bypass,
or aortoiliac bypass surgery. In the control subjects a 1-cm
segment of the pudendal artery was collected during the
varicose vein surgery. The presence of C pneumoniae DNA
was compared between samples from patients and control
subjects. A segment of varicose saphenous vein from the
control subjects was also obtained and processed. The
biopsy specimens were immediately washed with physio-
logic saline solution to remove any remaining blood or
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phosphate-glutamic acid buffer transport and preservation
medium. They were refrigerated at4°C to10°C for 12
to 16 hours, and then maintained at 70°C until analysis
with hemi-nested PCR.
A personal modification16 of the technique initially
described by Campbell et al17 was used. The samples were
homogenized, and DNA was extracted for enzymatic di-
gestion with proteinase K. The amount of DNA was
matched among samples (50-100 ng/mL). The first PCR
was carried out with the primers HL-1 (GTTGTTCAT-
GAAGGCCTACT) and HR-1 (TGCATAACCTACGGT-
GTGTT) with a Perkin-Elmer 9600 thermocycler, and
produced a fragment of 437 base pairs. A second PCR was
performed on this product, with primers HR-1 and HM-1
(GTGTCATTCGCCAAGGTTAA), and produced a
shorter fragment of only 229 base pairs. All primers were of
the Pst-1 segment. The reading was performed with elec-
trophoresis in 2% agarose gel. The -actin gene served as
internal control for DNA amplification and extraction.
To prevent false positive amplifications, procedures
recommended to prevent contamination were strictly ob-
served and all reactions were performed under stringent
conditions. All reagents were aliquoted and stored in dif-
ferent locations. PCR reagents were prepared before each
assay in a master mixture, which was then aliquoted. Prep-
aration of the master mixture, extraction of the DNA and
addition of the template to the PCR mixture, and thermal
cycling were performed in 3 different, well-separated
rooms, each with its own dedicated set of micropipettes and
gowns. Only aerosol-resistant barrier pipette tips were
used. Meticulous laboratory techniques and adherence to
standard PCR anti-contamination procedures were the
norm, including frequent glove changes and decontamina-
tion of surfaces with ultraviolet (UV) light and sodium
hypochlorite. All tubes, pipette tips, and reagents, except
for the primers and Taq polymerase, were exposed to 254
nm of UV light in a nucleic acid linker oven (Stratalinker
UV Crosslinker; Stratagene) before use. A number of neg-
ative controls (numerous negative water and PCR reagent-
only samples) were included in each PCR assay.
Statistical analysis. Statistical analysis was carried out
with the SPSS statistical package (version 10, 2001; SPSS
Inc). Exact logistic regression was performed with the
LogXact program (version 2.1, 1996; Civel Software
Corp). Continuous variables were compared with the Stu-
dent t test. Discrete variables were analyzed with the 2 test
or Fischer exact test; the Pearson correlation was used to
calculate the correlation among the variables. Exact logistic
regression was used to fit a multivariate model explaining
the presence of C pneumoniae, and the Hosmer-Lemeshow
test was applied to the adjusted model.
RESULTS
Adequate samples for analysis were obtained from all
114 study patients, with no accidental losses or destruction.
Patient baseline characteristics are shown in Table II. There
were no significant differences in the distribution of sex,tobacco exposure, or age above the 25th percentile be-
tween the two groups. The mean age of the patients was 6
years older than that of the control subjects.
Comparability. There were differences between the
groups in other covariables studied. Diabetes, hyperten-
sion, hypercholesterolemia, and hypertriglyceridemia oc-
curred much more frequently in patients compared with
control subjects. There was no significant difference in
obesity between the groups.
To fit a multivariate model explaining the presence or
absence of C pneumoniae between study groups, and taking
into account the sample size, exact logistic regression was
applied (Table III, online only). The only factor identified
as clearly and strongly significant was the effect of belong-
ing to the patient or control group (odds ratio [OR],
18.055; 95% confidence interval [CI], 4.260-76.527). The
high value of the OR estimated in this case may be ex-
plained by overestimation due to the sample size and strong
relationship between risk factors. The goodness of fit of the
adjusted model was verified with the Hosmer-Lemeshow
test, and was not significant (2  12.742; P  .121; 8
degrees of freedom). In addition, outliers and weighted
data were looked for; none were detected.
Marker of inflammation. Fibrinogen levels were
367.69  96.81 in patients versus 355  79.11 in control
subjects. This small difference was not statistically signifi-
cant (P  .454, Student t test). The value of the third
quartile was 422.25 mg/dL; 26.6% of patients had levels
above this value, versus 22% of control subjects. This dif-
ference was not statistically significant (P .574, 2 test).
The OR for fibrinogen above the 75th percentile was 1.282
(95% CI, 0.538-3.058).
Anti–C pneumoniae antibodies. These results are
shown in two ways: not grouped, either for MIF or ELISA
(Table IV; Fig 1), and analyzed as positive or negative
(Tables V and VI). With MIF and ELISA, titers for IgG
were 75% and 78%, respectively, in patients, versus 16% and
24%, respectively, in control subjects. This difference was
Table II. Baseline clinical characteristics of 64 subjects





(N  50) P




Male sex (%) 79.7 80 .967†
Smoking (past or current) (%) 71.9 60 .182†
Diabetes mellitus (%) 31.3 4 .0001‡
Hypertension (%) 53.1 8 .0001†
Hypercholesterolemia (%) 29.7 4 .0001‡
Hypertriglyceridemia (%) 28.1 8 .007†
Obesity (%) 26.6 28.2 .864†
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test), with an OR of 11.31 (95% CI, 4.696-27.236) for
MIF and 15.75 (95% CI, 6.126-40.495) for ELISA.
IgA seropositivity was 7.8% in patients, versus 16% in
control subjects. This difference was not statistically signif-
icant (P  .172, 2 test), with an OR of 0.445 (95% CI,
0.136-1.458).
Results for clinical subgroups considered, showing a
uniform distribution, are shown in Table VI.
C pneumoniae DNA. C pneumoniae DNA was de-
tected with PCR in 43 atheromatous plaques from patients
(67.2%) and 6 external pudendal arteries from control
subjects (12%; Figs 2 and 3), a statistically significant dif-
ference (P  .0001, 2 test). Table VI shows that the
presence of C pneumoniae DNA had a uniform distribution
among subgroups.
Detection of C pneumoniae DNA in saphenous vein
samples was considered separately. It was detected in 2
samples (4%) from 2 control subjects with positive DNA in
the external pudendal artery.
Table IV. Distribution of IgG-EB titers with MIF techniq
1/16 1/16
n % n %
Cases 4 6.25 10 15.6
Controls 30 60 8 16
IgG, Immunoglobulin G; EB, elementary body; MIF, microimmunofluoroe
*2 test.
Fig 1. Distribution of IgG and IgG antibody titers with e
1.1). IgG-EB, Immunoglobulin G elementary bodies; IgCorrelation between antibodies and intraplaque in-
fection. The relationship among the diagnostic capabili-
ties of the 3 serologic determinations was studied. Com-
parison between the 2 IgG antibody techniques showed
that both were positive in 47 patients and both were
negative in 43 patients (r 0.582, Pearson correlation; P
.001, 2). The results for intraplaque infection are exhib-
ited in Table VII. Although the correlation rates for IgG
were low, they were statistically significant. IgA antibodies
were not correlated with IgG or genomic detection.
DISCUSSION
The findings of the present case-control study support
the hypothesis that C pneumoniae has a role in atheroscle-
rosis, because the rates of seropositivity and DNA detection
were higher in patients than in matched control subjects.
The strengths of this study are that an adjusted case-control
design was followed, and serologic, clinical, and genomic
studies were performed.
1/32 1/64 1/128
% n % n %
17.2 21 32.8 18 28.1
16 4 8 0 0
P .0001*
e.
e-linked immunosorbent assay Technique (cutoff point,
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years who could supply an artery during a surgical interven-
tion and form a comparable control group. The control
subjects were selected after recruitment of the patients, to
control for the 2 main risk factors, age and sex. Although
patients with PAOD were significantly older, by 6 years,)
than control subjects, the model was comparable (Table
III). The control subjects were also matched for tobacco
use, to avert a possible bias reported in the literature.18
The extraction of a segment of the external pudendal
artery during conventional varicose vein surgery is a mini-
mal procedure, because this artery can normally be ligated if
required. The novelty of this work was the extraction of
arteries for analysis. There were no postoperative complica-










IgG-EB MIF 78.1 24 11.31 4.696–27.236
IgG-EB ELISA 75 16 15.75 6.126–40.495
IgA-EB ELISA 7.8 16 0.445 0.136–1.456
Ig, Immunoglobulin; EB, elementary body; MIF, microimmunofluores-
cence; ELISA, enzyme-linked immunosorbent assay.
Table VI. Seropositivity of different antibodies against
elementary bodies of Chlamydia pneumoniae and DNA







MIF IgG-EB 77.8 90 69.2 .240
ELISA IgG-EB 61.1 85 76.9 .227
ELISA IgA-EB 11.1 0 15.0 .142
DNA Positive 66.7 65 69.2 .954
MIF, Microimmunofluorescence; ELISA, enzyme-linked immunosorbent
assay; Ig, immunoglobulin; EB, elementary body.
*2 test.
Table VII. Correlation between seropositivity according
to different serologic techniques and intraplaque infection











IgG-EB (MIF) 37 0.368 .0001 4.03 2.17–11.21
IgG-EB (ELISA) 36 0.423 .0001 6.23 2.73–14.21
IgA-EB (ELISA) 3 0.144 .112 0.36 0.09–1.38
Ig, Immunoglobulin; EB, elementary body; MIF, microimmunofluores-
cence; ELISA, enzyme-linked immunosorbent assay.
*Pearson coefficient.
†2 test.tions attributable to extraction of biopsy specimens of
external pudendal artery.
Fibrinogen levels, as a marker of inflammation and
chronic infection, were slightly higher in the PAOD group,
Fig 2. Detection of Chlamydia pneumoniae DNA in samples of
vascular tissue detected with polymerase chain reaction in 43 of 64
atheromatous plaques from patients, 6 of 50 external pudendal
arteries from control subjects, and 2 of 50 saphenous veins.
Fig 3. Amplification of Chlamydia pneumoniae DNA (agarose
gel). Lane 1, MW 154-2176 bp; lane 2, negative control; lane 3,
positive sample; lane 4, negative sample; lane 5, MW 8-578 bp. bp,
Base pairs.
JOURNAL OF VASCULAR SURGERY
August 2004364 Linares-Palomino et alalthough the difference did not reach statistical signifi-
cance. Variable data have been reported by other au-
thors.19,20
Seropositivity for IgG-EB with MIF was defined at a
high level of greater than 1:32 titers, because in a recent
workshop on standardization of C pneumoniae diagnostic
methods the Centers for Disease Control and Prevention
regarded an IgG titer greater than 16 as indicating past
exposure.21 We believe that we increased the specificity of
the test by using a cutoff titer greater than 1:32. The ELISA
technique, which obviates this problem, showed similar
seropositivity values as the MIF results.
The OR ratios are higher than in previous reports, with
only a few studies22-24 showing ORs within this range;
however, bear in mind that thresholds for seropositivity are
highly variable. There have been no reports of ORs above
10 with ELISA, although this remains a little-used tech-
nique.15,22,25
Our findings for IgA-EB are comparable with recent
studies, which also found low rates of seropositivity.3,24,26
Results of published seroepidemiologic case-control stud-
ies are conflicting, with some27-29 reporting that seroposi-
tivity to C pneumoniae is associated with arterial disease and
others26,30 reporting that it is not. Even case-control stud-
ies published by the Atherosclerosis Risk in Communities
study researchers came to divergent conclusions, with an
OR of 2.00 for seropositivity in patients with stroke27 but
no association in patients with coronary heart disease.31
An issue that is yet to be resolved is the type of antigen
to be used in serologic testing. Traditionally lipopolysac-
charide has been used, but tests are now available against
EB and other epitopes, promising improved sensitivity and
specificity. The genomic study found C pneumoniae DNA
in 67.2% of samples of diseased arteries versus 12% of
atheroma-free arteries. PCR is a highly specific technique,
and provides a reliable diagnosis.17 We used a hemi-nested
PCR, thereby achieving virtually total certainty that the
DNA fragments found were of C pneumoniae.18-20,22-32
However, the histologic structure of the pudendal artery is
different from that of the femoral or carotid arteries, and it
rarely is associated with atherosclerosis. We believe that the
artery of a live person always offers better evidence than that
of a cadaveric artery, used in other studies.33-35 The main
advantage of our approach is that a real case-control study
can be performed with arterial tissue from comparable
subjects.
Twenty-two case-control studies that examined the
presence of C pneumoniae in non-coronary atheromatous
plaques with PCR have been published. In 8 studies the
controls were apparently healthy arteries from patients; the
DNA was detected in 0% to 76% of patients and 0% to 53%
of control samples33,36 (Table VIII, online only). We de-
tected the DNA in 67% of patients versus 12% of control
subjects. We have no explanation for our finding of C
pneumoniae DNA in 6 control arteries, especially when 4 of
them demonstrated negative serologic findings. This situ-
ation has been reported by other authors.31,36,37 We are
also unable to explain the presence of C pneumoniae DNAin 2 of 50 samples of varicose saphenous vein. Varicose vein
walls can have a certain degree of inflammation,38 and we
could not determine whether the DNA came from vascular
wall cells or from macrophages.
Our study shows poor correlation between seropositiv-
ity and C pneumoniae DNA detection, and only for IgG-
EB. Few studies have found any relationship, and always
with a larger sample size than ours.24,37
For infection to be a risk factor,10,11 independent of
other risk factors such as hyperlipidemia, tobacco use,
hypertension, diabetes, or family history of the disease, it is
necessary to address the action mechanism by which C
pneumoniae produces atherosclerosis and to determine
whether C pneumoniae causes the initial damage, trigger-
ing the atherosclerosis, or accelerates and aggravates previ-
ous atheromatous lesions. Even atherosclerotic plaques,
with their high leukocyte content, may be a site where C
pneumoniae is merely present without participating in the
pathogenesis of atherosclerosis.
It is not possible to deduce from our study the causal
relationship between chronic C pneumoniae infection and
PAOD. However, the high seropositivity rate in the pa-
tients and the frequent detection of viable C pneumoniae in
the atheromatous plaques suggest that C pneumoniae in-
fection has some role in the pathogenesis of atherosclerosis.
Our finding of DNA in healthy arteries and varicose veins in
patients without clinical PAOD can be variously interpreted
as evidence for and against the participation of C pneu-
moniae in atherosclerosis.
In conclusion, the findings of our matched case-control
study further support the relationship between C pneu-
moniae infection and PAOD. Wider case-control studies of
comparable subjects are warranted to definitively establish
whether some chronic infections can induce atherosclero-
sis.
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